These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 30010839)

  • 1. Association of the rs495392 Klotho polymorphism with atheromatosis progression in patients with chronic kidney disease.
    Valdivielso JM; Bozic M; Galimudi RK; Bermudez-López M; Navarro-González JF; Fernández E; Betriu À
    Nephrol Dial Transplant; 2019 Dec; 34(12):2079-2088. PubMed ID: 30010839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of Subclinical Atheromatosis Progression over 2 Years in Patients with Different Stages of CKD.
    Gracia M; Betriu À; Martínez-Alonso M; Arroyo D; Abajo M; Fernández E; Valdivielso JM;
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):287-96. PubMed ID: 26668022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of FGF-2 Concentrations with Atheroma Progression in Chronic Kidney Disease Patients.
    Bozic M; Betriu A; Bermudez-Lopez M; Ortiz A; Fernandez E; Valdivielso JM;
    Clin J Am Soc Nephrol; 2018 Apr; 13(4):577-584. PubMed ID: 29519952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble TWEAK and atheromatosis progression in patients with chronic kidney disease.
    Fernández-Laso V; Méndez-Barbero N; Valdivielso JM; Betriu A; Fernández E; Egido J; Martín-Ventura JL; Blanco-Colio LM
    Atherosclerosis; 2017 May; 260():130-137. PubMed ID: 28390291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Observational multicenter study to evaluate the prevalence and prognosis of subclinical atheromatosis in a Spanish chronic kidney disease cohort: baseline data from the NEFRONA study.
    Arroyo D; Betriu A; Martinez-Alonso M; Vidal T; Valdivielso JM; Fernández E;
    BMC Nephrol; 2014 Oct; 15():168. PubMed ID: 25326683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors predicting cardiovascular events in chronic kidney disease patients. Role of subclinical atheromatosis extent assessed by vascular ultrasound.
    Valdivielso JM; Betriu A; Martinez-Alonso M; Arroyo D; Bermudez-Lopez M; Fernandez E;
    PLoS One; 2017; 12(10):e0186665. PubMed ID: 29045466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of subclinical atheromatosis and associated risk factors in chronic kidney disease: the NEFRONA study.
    Betriu A; Martinez-Alonso M; Arcidiacono MV; Cannata-Andia J; Pascual J; Valdivielso JM; Fernández E;
    Nephrol Dial Transplant; 2014 Jul; 29(7):1415-22. PubMed ID: 24586070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of serum phosphorus with subclinical atherosclerosis in chronic kidney disease. Sex makes a difference.
    Martín M; Valls J; Betriu A; Fernández E; Valdivielso JM
    Atherosclerosis; 2015 Jul; 241(1):264-70. PubMed ID: 25748053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between low levels of circulating TRAIL and atheromatosis progression in patients with chronic kidney disease.
    Arcidiacono MV; Rimondi E; Maietti E; Melloni E; Tisato V; Gallo S; Valdivielso JM; Fernández E; Betriu À; Voltan R; Zauli G; Volpato S; Secchiero P
    PLoS One; 2018; 13(9):e0203716. PubMed ID: 30204795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix Gla protein polymorphism rs1800802 is associated with atheroma plaque progression and with cardiovascular events in a chronic kidney disease cohort.
    Cambray S; Bermúdez-López M; Garcia-Carrasco A; Valdivielso JM;
    Clin Kidney J; 2024 Jan; 17(1):sfad257. PubMed ID: 38186884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of femoral artery ultrasound measures of atherosclerosis with chronic kidney disease.
    Hsu S; Rifkin DE; Criqui MH; Suder NC; Garimella P; Ginsberg C; Marasco AM; McQuaide BJ; Barinas-Mitchell EJ; Allison MA; Wassel CL; Ix JH
    J Vasc Surg; 2018 Jun; 67(6):1855-1863.e1. PubMed ID: 29276107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and progression of subclinical atherosclerosis in patients with chronic kidney disease and diabetes.
    Palanca A; Castelblanco E; Perpiñán H; Betriu À; Soldevila B; Valdivielso JM; Bermúdez M; Duran X; Fernández E; Puig-Domingo M; Groop PH; Alonso N; Mauricio D
    Atherosclerosis; 2018 Sep; 276():50-57. PubMed ID: 30032025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of a single nucleotide polymorphism combination pattern of the Klotho gene with non-cardiovascular death in patients with chronic kidney disease.
    Cambray S; Bermudez-Lopez M; Bozic M; Valdivielso JM;
    Clin Kidney J; 2020 Dec; 13(6):1017-1024. PubMed ID: 33391745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cumulative tobacco consumption has a dose-dependent effect on atheromatosis burden and improves severe atheromatosis prediction in asymptomatic middle-aged individuals: The ILERVAS study.
    Bermúdez-López M; Martí-Antonio M; Castro-Boqué E; Bretones MDM; Farràs C; Gonzalez J; Pamplona R; Lecube A; Mauricio D; Cambray S; Valdivielso JM; Fernández E;
    Atherosclerosis; 2023 Jun; 375():75-83. PubMed ID: 37276714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subclinical atheromatosis localization and burden in a low-to-moderate cardiovascular risk population: the ILERVAS study.
    Bermúdez-López M; Martínez-Alonso M; Castro-Boqué E; Betriu À; Cambray S; Farràs C; Barbé F; Pamplona R; Lecube A; Mauricio D; Purroy F; Valdivielso JM; Fernández E;
    Rev Esp Cardiol (Engl Ed); 2021 Dec; 74(12):1042-1053. PubMed ID: 33162389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of matrix Gla protein, Klotho gene polymorphisms, and oxidative stress in chronic kidney disease.
    Karsli Ceppioğlu S; Yurdun T; Canbakan M
    Ren Fail; 2011; 33(9):866-74. PubMed ID: 21859400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].
    Milovanova LY; Milovanov YS; Kudryavtseva DV; Markina MM; Milovanova SY; Kozlovskaya LV; Lebedeva MV; Beketov VD; Moiseev SV; Mukhin NA; Fomin VV; Svistunov AA
    Ter Arkh; 2015; 87(6):10-16. PubMed ID: 26281189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Klotho as a biomarker of subclinical atherosclerosis in patients with moderate to severe chronic kidney disease.
    Donate-Correa J; Ferri CM; Martín-Núñez E; Pérez-Delgado N; González-Luis A; Mora-Fernández C; Navarro-González JF
    Sci Rep; 2021 Aug; 11(1):15877. PubMed ID: 34354161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating α-klotho levels in CKD and relationship to progression.
    Kim HR; Nam BY; Kim DW; Kang MW; Han JH; Lee MJ; Shin DH; Doh FM; Koo HM; Ko KI; Kim CH; Oh HJ; Yoo TH; Kang SW; Han DS; Han SH
    Am J Kidney Dis; 2013 Jun; 61(6):899-909. PubMed ID: 23540260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study.
    Tranæus Lindblad Y; Olauson H; Vavilis G; Hammar U; Herthelius M; Axelsson J; Bárány P
    Pediatr Nephrol; 2018 Jan; 33(1):147-157. PubMed ID: 28795324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.